Please verify that you are a Healthcare Professional. Register for complete access to all the content!
Tapinarof 1% shows strong safety profile in psoria...
A growing body of clinical and real-world evidence highlights tapinarof (aryl hydrocarbon receptor agonist) cream 1% as a well-tolerated and flex...
Saline rinse + Aze-Flu spray offers excellent reli...
According to the findings of a recent study, saline irrigation enhances the therapeutic effect of azelastine–fluticasone (Aze-Flu), leading...
1 min
Tapinarof 1% offers clinically meaningful relief i...
Tapinarof 1% cream administered once per day remarkably improves disease severity and pruritus in atopic dermatitis (AD), according to the outcom...
1 min
Comparison of intranasal vs. oral therapies for AR...
Allergic rhinitis (AR) is a prevalent ailment typically managed with intranasal or oral medications.
2 min
Budesonide nasal spray improves symptom control in...
Chronic idiopathic urticaria (CIU), a distressing condition marked by persistent hives, intense itching, and episodic angioedema lasting longer t...
1 min
Respiratory allergy testing: A comparative review...
Accurate identification of allergen sensitization plays a crucial role in the management of asthma and allergic rhinitis (AR), with diagnostic ap...
1 min
Network meta-analysis identifies INAH+INCS as top-...
A major systematic review and network meta-analysis of 167 trials has clarified the comparative safety and efficiency of intranasal antihistamine...
1 min
Pollen emerges as leading trigger of childhood all...
A large study has found that pollen—especially grasses from the Poaceae family—is the most common cause of clinically relevant aeroal...
2 min
Cetirizine among top performers for nasal symptoms...
A large network meta-analysis explored the efficacy and safety of oral H1-antihistamines in allergic rhinitis (AR) by synthesizing evidence from...
1 min
OM-85 shows immunomodulatory benefits in children...
Allergic rhinitis (AR) is a common chronic ailment in children that markedly affects daily activities, emotional wellbeing, and overall quality o...
2 min
OM-85 add-on therapy improves control in T2-high asthma
OM-85 add-on therapy significantly reduces asthma exacerbations and corticosteroid dependence in patients with difficult-to-control T2-high asthm...
New prognostic model identifies key risk factors for incontinence...
A newly developed predictive model identifies mobility decline, reduced functional independence, and skin characteristics as major indicators of...
Japanese study reveals biomarker-specific itch patterns in atopic...
Specific itch sensations in atopic dermatitis are associated with different inflammatory biomarkers, with crawling linked to IL-31 and stinging/s...
Six-year safety evaluation of upadacitinib in moderate-to-severe...
Upadacitinib demonstrates a stable long-term safety profile in moderate-to-severe atopic dermatitis over six years, with no new or unexpected saf...
New international urticaria guideline advances biomarker-guided d...
Updated international urticaria guidelines recommend precision-based diagnosis, biomarker-guided evaluation, and stepwise escalation to targeted...
Rapid assessment of chronic spontaneous urticaria activity using...
First-day urticaria activity score (UAS1) accurately reflects weekly disease activity and quality-of-life impairment in chronic spontaneous urtic...
Breastfeeding for ≥4 months linked to lower asthma risk through e...
Exclusive breastfeeding for a minimum of four months is linked to lower asthma risk and reduced allergic responsiveness from childhood through yo...
Real-world survey exposes treatment challenges in allergic rhinit...
Allergic rhinitis management shows substantial gaps, including low healthcare engagement, poor treatment adherence, and limited use of advanced a...
Canadian experts update guidance on allergic rhinitis diagnosis a...
New Canadian AR guidance supports flexible diagnostic testing, individualized first-line therapy selection, and broader use of SLIT and SCIT whil...
Intranasal antihistamines and corticosteroids for AR: Insights fr...
Fixed intranasal antihistamine–corticosteroid combinations demonstrate superior quality-of-life and health utility outcomes in allergic rhi...
Remibrutinib in CSU: Findings from Phase 3 BISCUIT study
Remibrutinib (25 mg twice daily) rapidly improves itch and hives in chronic spontaneous urticaria and sustains symptom control over 52 weeks with...
Cetirizine among top performers for nasal symptoms in allergic rh...
Cetirizine, ebastine, and rupatadine perform better for nasal symptoms, while loratadine and desloratadine show relatively better effects on ocul...
This website uses cookies to help us give you the best experience when you visit.
By using this website you consent to our use of cookies. For more information please review our cookie policy.